{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:38:54Z","timestamp":1792215534099,"version":"4.4.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40272-020-00413-3","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T11:05:58Z","timestamp":1598699158000},"page":"485-499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges"],"prefix":"10.1007","volume":"22","author":[{"given":"Sylwia","family":"Jasinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Andrew","family":"De Los Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Contreras","family":"Yametti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Pierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Raetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-4167","authenticated-orcid":false,"given":"William L.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"issue":"1","key":"413_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"413_CR2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30(14):1663\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"413_CR3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/leu.2009.261","volume":"24","author":"WL Salzer","year":"2010","unstructured":"Salzer WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984\u20132001: a report from the children\u2019s oncology group. Leukemia. 2010;24(2):355\u201370.","journal-title":"Leukemia"},{"issue":"2","key":"413_CR4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2009.262","volume":"24","author":"PS Gaynon","year":"2010","unstructured":"Gaynon PS, et al. Long-term results of the children\u2019s cancer group studies for childhood acute lymphoblastic leukemia 1983\u20132002: a Children\u2019s Oncology Group Report. Leukemia. 2010;24(2):285\u201397.","journal-title":"Leukemia"},{"issue":"12","key":"413_CR5","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"K Nguyen","year":"2008","unstructured":"Nguyen K, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia. 2008;22(12):2142\u201350.","journal-title":"Leukemia"},{"issue":"5","key":"413_CR6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","volume":"130","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. Blood. 2017;130(5):677\u201385.","journal-title":"Blood"},{"issue":"9617","key":"413_CR7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030\u201343.","journal-title":"Lancet"},{"issue":"1","key":"413_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpeds.2011.08.006","volume":"160","author":"WL Carroll","year":"2012","unstructured":"Carroll WL, Raetz EA. Clinical and laboratory biology of childhood acute lymphoblastic leukemia. J Pediatr. 2012;160(1):10\u20138.","journal-title":"J Pediatr"},{"issue":"4","key":"413_CR9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2040620713498161","volume":"4","author":"E Stieglitz","year":"2013","unstructured":"Stieglitz E, Loh ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013;4(4):270\u201390.","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"413_CR10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/leu.2014.322","volume":"29","author":"D Alpar","year":"2015","unstructured":"Alpar D, et al. Clonal origins of ETV6-RUNX1(+) acute lymphoblastic leukemia: studies in monozygotic twins. Leukemia. 2015;29(4):839\u201346.","journal-title":"Leukemia"},{"issue":"1","key":"413_CR11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/gcc.20010","volume":"40","author":"AT Maia","year":"2004","unstructured":"Maia AT, et al. Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukemia in cord blood. Genes Chromosomes Cancer. 2004;40(1):38\u201343.","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"413_CR12","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-12-3817","volume":"102","author":"MF Greaves","year":"2003","unstructured":"Greaves MF, et al. Leukemia in twins: lessons in natural history. Blood. 2003;102(7):2321\u201333.","journal-title":"Blood"},{"issue":"9","key":"413_CR13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrc1164","volume":"3","author":"MF Greaves","year":"2003","unstructured":"Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3(9):639\u201349.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"413_CR14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/cncr.31099","volume":"124","author":"WL Salzer","year":"2018","unstructured":"Salzer WL, et al. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the Children\u2019s Oncology Group study AALL1131. Cancer. 2018;124(6):1150\u20139.","journal-title":"Cancer"},{"issue":"21","key":"413_CR15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V124.21.793.793","volume":"124","author":"LA Mattano","year":"2014","unstructured":"Mattano LA, et al. Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children\u2019s Oncology Group (COG) Study AALL0331. Blood. 2014;124(21):793.","journal-title":"Blood"},{"issue":"2","key":"413_CR16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2010-12-322909","volume":"118","author":"Y Matloub","year":"2011","unstructured":"Matloub Y, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood. 2011;118(2):243\u201351.","journal-title":"Blood"},{"issue":"5","key":"413_CR17","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","volume":"111","author":"NL Seibel","year":"2008","unstructured":"Seibel NL, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood. 2008;111(5):2548\u201355.","journal-title":"Blood"},{"issue":"1","key":"413_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","volume":"36","author":"D O\u2019Connor","year":"2018","unstructured":"O\u2019Connor D, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36(1):34\u201343.","journal-title":"J Clin Oncol"},{"issue":"8","key":"413_CR19","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.leu.2403001","volume":"17","author":"MJ Borowitz","year":"2003","unstructured":"Borowitz MJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children\u2019s Oncology Group study. Leukemia. 2003;17(8):1566\u201372.","journal-title":"Leukemia"},{"issue":"22","key":"413_CR20","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","volume":"35","author":"N Winick","year":"2017","unstructured":"Winick N, et al. Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2017;35(22):2527\u201334.","journal-title":"J Clin Oncol"},{"issue":"6","key":"413_CR21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","volume":"38","author":"KW Maloney","year":"2020","unstructured":"Maloney KW, et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0331. J Clin Oncol. 2020;38(6):602\u201312.","journal-title":"J Clin Oncol"},{"issue":"23","key":"413_CR22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V126.23.807.807","volume":"126","author":"E Raetz","year":"2015","unstructured":"Raetz E, et al. Genetic and response-based risk classification identifies a subgroup of NCI high risk childhood B-lymphoblastic leukemia (HR B-ALL) with outstanding outcomes: a report from the Children\u2019s Oncology Group (COG). Blood. 2015;126(23):807.","journal-title":"Blood"},{"issue":"2","key":"413_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40124-015-0078-8","volume":"3","author":"JL McNeer","year":"2015","unstructured":"McNeer JL, Raetz EA. Childhood acute lymphoblastic leukemia: toward personalized medicine. Curr Pediatr Rep. 2015;3(2):111\u20138.","journal-title":"Curr Pediatr Rep"},{"issue":"9142","key":"413_CR24","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","volume":"352","author":"JJ van Dongen","year":"1998","unstructured":"van Dongen JJ, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731\u20138.","journal-title":"Lancet"},{"issue":"12","key":"413_CR25","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","volume":"111","author":"MJ Borowitz","year":"2008","unstructured":"Borowitz MJ, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study. Blood. 2008;111(12):5477\u201385.","journal-title":"Blood"},{"issue":"10","key":"413_CR26","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861","volume":"86","author":"E Klumper","year":"1995","unstructured":"Klumper E, et al. In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukemia. Blood. 1995;86(10):3861\u20138.","journal-title":"Blood"},{"issue":"1","key":"413_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1040-8428(96)00223-5","volume":"25","author":"R Pieters","year":"1997","unstructured":"Pieters R, et al. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol. 1997;25(1):11\u201326.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"413_CR28","first-page":"5667","volume":"35","author":"M Pogorzala","year":"2015","unstructured":"Pogorzala M, et al. Drug-resistance profile in multiple-relapsed childhood acute lymphoblastic leukemia. Anticancer Res. 2015;35(10):5667\u201370.","journal-title":"Anticancer Res"},{"issue":"19","key":"413_CR29","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1182\/blood-2011-04-345595","volume":"118","author":"LE Hogan","year":"2011","unstructured":"Hogan LE, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011;118(19):5218\u201326.","journal-title":"Blood"},{"issue":"10","key":"413_CR30","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1182\/blood-2008-06-165027","volume":"112","author":"JJ Yang","year":"2008","unstructured":"Yang JJ, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008;112(10):4178\u201383.","journal-title":"Blood"},{"issue":"5","key":"413_CR31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2017.176362","volume":"103","author":"NA Evensen","year":"2018","unstructured":"Evensen NA, et al. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica. 2018;103(5):830\u20139.","journal-title":"Haematologica"},{"issue":"5906","key":"413_CR32","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377\u201380.","journal-title":"Science"},{"issue":"30","key":"413_CR33","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1074\/jbc.M114.569889","volume":"289","author":"CL Jones","year":"2014","unstructured":"Jones CL, et al. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem. 2014;289(30):20502\u201315.","journal-title":"J Biol Chem"},{"issue":"23","key":"413_CR34","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1182\/blood-2009-05-223081","volume":"115","author":"JC van Galen","year":"2010","unstructured":"van Galen JC, et al. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood. 2010;115(23):4810\u20139.","journal-title":"Blood"},{"issue":"19","key":"413_CR35","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2015-04-639138","volume":"126","author":"CL Jones","year":"2015","unstructured":"Jones CL, et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015;126(19):2202\u201312.","journal-title":"Blood"},{"issue":"23","key":"413_CR36","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","volume":"124","author":"J Irving","year":"2014","unstructured":"Irving J, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420\u201330.","journal-title":"Blood"},{"issue":"3","key":"413_CR37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","volume":"45","author":"JA Meyer","year":"2013","unstructured":"Meyer JA, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013;45(3):290\u20134.","journal-title":"Nat Genet"},{"issue":"6","key":"413_CR38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nm.3840","volume":"21","author":"B Li","year":"2015","unstructured":"Li B, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med. 2015;21(6):563\u201371.","journal-title":"Nat Med"},{"key":"413_CR39","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1038\/ncomms4469","volume":"5","author":"BG Mar","year":"2014","unstructured":"Mar BG, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014;5:3469.","journal-title":"Nat Commun"},{"issue":"6","key":"413_CR40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPH.0000000000000179","volume":"36","author":"T Bhatla","year":"2014","unstructured":"Bhatla T, et al. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Pediatr Hematol Oncol. 2014;36(6):413\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"413_CR41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-02-002824","volume":"108","author":"D Bhojwani","year":"2006","unstructured":"Bhojwani D, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Blood. 2006;108(2):711\u20137.","journal-title":"Blood"},{"key":"413_CR42","doi-asserted-by":"crossref","unstructured":"Lew, G., et al., Outcomes after late bone marrow and very early central nervous system relapse of childhood B-Acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group phase III study AALL0433. Haematologica, 2020.","DOI":"10.3324\/haematol.2019.237230"},{"issue":"36","key":"413_CR43","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1200\/JCO.19.01694","volume":"37","author":"C Eckert","year":"2019","unstructured":"Eckert C, et al. Improving stratification for children with late bone marrow B-cell acute lymphoblastic leukemia relapses with refined response classification and integration of genetics. J Clin Oncol. 2019;37(36):3493\u2013506.","journal-title":"J Clin Oncol"},{"key":"413_CR44","doi-asserted-by":"crossref","unstructured":"Brown, P.A., et al., A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR\/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents\/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children\u2019s Oncology Group Study AALL1331. Blood, 2019. 134(Supplement_2): p. LBA-1-LBA-1.","DOI":"10.1182\/blood-2019-132435"},{"key":"413_CR45","doi-asserted-by":"crossref","unstructured":"Rheingold, S.R., et al., Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children\u2019s Oncology Group (COG) study. 2019. 37(15_suppl): p. 10008.","DOI":"10.1200\/JCO.2019.37.15_suppl.10008"},{"issue":"9","key":"413_CR46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","volume":"317","author":"D Nagorsen","year":"2011","unstructured":"Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255\u201360.","journal-title":"Exp Cell Res"},{"issue":"1","key":"413_CR47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"issue":"4","key":"413_CR48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40262-019-00823-8","volume":"59","author":"JD Clements","year":"2020","unstructured":"Clements JD, et al. Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. Clin Pharmacokinet. 2020;59(4):463\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"36","key":"413_CR49","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134\u201340.","journal-title":"J Clin Oncol"},{"issue":"1","key":"413_CR50","first-page":"56","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, et al. Cytokine release syndrome. J Immunother. Cancer. 2018;6(1):56.","journal-title":"Cancer"},{"issue":"4","key":"413_CR51","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"413_CR52","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/bloodadvances.2019000874","volume":"4","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, et al. Blinatumomab consolidation and maintenance therapy in adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia. Blood Adv. 2020;4(7):1518\u201325.","journal-title":"Blood Adv"},{"issue":"8","key":"413_CR53","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387\u201398.","journal-title":"Lancet Haematol"},{"issue":"14","key":"413_CR54","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522\u201331.","journal-title":"Blood"},{"issue":"16","key":"413_CR55","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, et al. Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. J Clin Oncol. 2017;35(16):1795\u2013802.","journal-title":"J Clin Oncol"},{"issue":"2","key":"413_CR56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.32558","volume":"126","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 2020;126(2):304\u201310.","journal-title":"Cancer"},{"issue":"36","key":"413_CR57","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, et al. Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"413_CR58","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858\u201365.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"413_CR59","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2018-99-113604","volume":"132","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, et al. Genomic Determinants of Response to Blinatumomab in Relapsed\/Refractory (R\/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. Blood. 2018;132(Supplement 1):1552.","journal-title":"Blood"},{"key":"413_CR60","doi-asserted-by":"crossref","unstructured":"Locatelli, F., et al., Blinatumomab versus historical standard therapy in pediatric patients with relapsed\/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia, 2020.","DOI":"10.1038\/s41375-020-0770-8"},{"issue":"Supplement 1","key":"413_CR61","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2018-99-112269","volume":"132","author":"LB Hogan","year":"2018","unstructured":"Hogan LB, et al. Induction toxicities are more frequent in young adults compared to children treated on the Children\u2019s Oncology Group (COG) first relapse B-lymphoblastic leukemia clinical trial AALL1331. Blood. 2018;132(Supplement 1):1382.","journal-title":"Blood"},{"key":"413_CR62","unstructured":"Locatelli F, Zugmaier G, Rizzari C, et al. Superior event-free survival with blinatumomab versus chemotherapy in children with high-risk first relapse of B-cell precursor acute lymphoblastic leukemia: a randomized, controlled phase 3 trial. Presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation. Madrid, Spain; 2020."},{"issue":"17","key":"413_CR63","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.2019004008","volume":"135","author":"K Clesham","year":"2020","unstructured":"Clesham K, et al. Blinatumomab for infant acute lymphoblastic leukemia. Blood. 2020;135(17):1501\u20134.","journal-title":"Blood"},{"issue":"10","key":"413_CR64","doi-asserted-by":"crossref","first-page":"e27898","DOI":"10.1002\/pbc.27898","volume":"66","author":"S Elitzur","year":"2019","unstructured":"Elitzur S, et al. Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. Pediatr Blood Cancer. 2019;66(10):e27898.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"413_CR65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.24987","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, et al. Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018;93(3):371\u20134.","journal-title":"Am J Hematol"},{"issue":"11","key":"413_CR66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood.2019002132","volume":"135","author":"I Aldoss","year":"2020","unstructured":"Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood. 2020;135(11):804\u201313.","journal-title":"Blood"},{"issue":"4","key":"413_CR67","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","volume":"102","author":"N Gokbuget","year":"2017","unstructured":"Gokbuget N, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102(4):e132\u20135.","journal-title":"Haematologica"},{"issue":"8","key":"413_CR68","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"6","key":"413_CR69","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","volume":"62","author":"NN Shah","year":"2015","unstructured":"Shah NN, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(6):964\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"413_CR70","unstructured":"BESPONSA\u00ae (inotuzumab ozogamicin). Full Prescribing Information. New York, N., USA: Pfizer Inc; 2017."},{"issue":"11","key":"413_CR71","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","volume":"21","author":"JF Dijoseph","year":"2007","unstructured":"Dijoseph JF, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240\u20135.","journal-title":"Leukemia"},{"key":"413_CR72","doi-asserted-by":"crossref","unstructured":"Shor, B., H.P. Gerber, and P. Sapra, Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol, 2015. 67(2 Pt A): p. 107-16.","DOI":"10.1016\/j.molimm.2014.09.014"},{"issue":"2","key":"413_CR73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/ejh.12408","volume":"94","author":"C Le Jeune","year":"2015","unstructured":"Le Jeune C, Thomas X. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur J Haematol. 2015;94(2):99\u2013108.","journal-title":"Eur J Haematol"},{"issue":"12","key":"413_CR74","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","volume":"28","author":"A Advani","year":"2010","unstructured":"Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085\u201393.","journal-title":"J Clin Oncol"},{"issue":"15","key":"413_CR75","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv. 2017;1(15):1167\u201380.","journal-title":"Blood Adv"},{"issue":"15","key":"413_CR76","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728\u201336.","journal-title":"Cancer"},{"issue":"14","key":"413_CR77","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474\u201387.","journal-title":"Cancer"},{"key":"413_CR78","doi-asserted-by":"crossref","first-page":"106283","DOI":"10.1016\/j.leukres.2019.106283","volume":"88","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, et al. Impact of minimal residual disease status in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020;88:106283.","journal-title":"Leuk Res"},{"issue":"4","key":"413_CR79","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884\u201392.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"413_CR80","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1182\/blood-2018-99-116360","volume":"132","author":"C Calvo","year":"2018","unstructured":"Calvo C, et al. Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Blood. 2018;132(Supplement 1):5203.","journal-title":"Blood"},{"key":"413_CR81","doi-asserted-by":"crossref","unstructured":"Fuster, J.L., et al., Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Br J Haematol, 2020.","DOI":"10.1111\/bjh.16647"},{"key":"413_CR82","doi-asserted-by":"crossref","unstructured":"Brivio, E., et al., A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2019. 134(Supplement_1): p. 3890.","DOI":"10.1182\/blood-2019-126472"},{"key":"413_CR83","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, M.M., et al., A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R\/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children\u2019s Oncology Group Protocol AALL1621. Blood, 2019. 134(Supplement_1): p. 741.","DOI":"10.1182\/blood-2019-128977"},{"issue":"4","key":"413_CR84","doi-asserted-by":"crossref","first-page":"e27562","DOI":"10.1002\/pbc.27562","volume":"66","author":"L Murillo","year":"2019","unstructured":"Murillo L, et al. Use of inotuzumab-ozogamicin in a child with Down syndrome and refractory B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66(4):e27562.","journal-title":"Pediatr Blood Cancer"},{"key":"413_CR85","unstructured":"European Medicines Agency. Besponsa (inotuzumab ozogamicin): EU summary of product characteristics. 2017. https:\/\/www.ema.europa.eu. Accessed 10 May 2020."},{"issue":"12","key":"413_CR86","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","volume":"33","author":"M Mohty","year":"2019","unstructured":"Mohty M, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33(12):2767\u201378.","journal-title":"Leukemia"},{"issue":"6","key":"413_CR87","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"key":"413_CR88","doi-asserted-by":"crossref","unstructured":"Graham, C., et al., Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies. Blood, 2019. 134(Supplement_1): p. 3228.","DOI":"10.1182\/blood-2019-123018"},{"issue":"5","key":"413_CR89","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"16","key":"413_CR90","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"26","key":"413_CR91","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019;134(26):2361\u20138.","journal-title":"Blood"},{"issue":"25","key":"413_CR92","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u201331.","journal-title":"Blood"},{"issue":"9967","key":"413_CR93","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet"},{"key":"413_CR94","unstructured":"Shah, N.N., et al., CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. 0(0): p. JCO.19.03279."},{"issue":"1","key":"413_CR95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MOP.0000000000000436","volume":"29","author":"SL Maude","year":"2017","unstructured":"Maude SL. Future directions in chimeric antigen receptor T cell therapy. Curr Opin Pediatr. 2017;29(1):27\u201333.","journal-title":"Curr Opin Pediatr"},{"issue":"1","key":"413_CR96","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2016.1257606","volume":"22","author":"F Huguet","year":"2017","unstructured":"Huguet F, Tavitian S. Emerging biological therapies to treat acute lymphoblastic leukemia. Expert Opin Emerg Drugs. 2017;22(1):107\u201321.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"413_CR97","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390.","journal-title":"Nat Med"},{"key":"413_CR98","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","volume":"65","author":"DM Barrett","year":"2014","unstructured":"Barrett DM, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333\u201347.","journal-title":"Annu Rev Med"},{"issue":"6","key":"413_CR99","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338.","journal-title":"J Clin Invest"},{"key":"413_CR100","unstructured":"KYMRIAH\u00ae (tisagenlecleucel). Full Prescribing Information. East Hanover, NJ., USA: Novartis Pharmaceuticals Corporation; 2017."},{"issue":"8","key":"413_CR101","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453\u201364.","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"413_CR102","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2018-99-115460","volume":"132","author":"MA Pulsipher","year":"2018","unstructured":"Pulsipher MA, et al. Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel. Blood. 2018;132(Supplement 1):1551.","journal-title":"Blood"},{"issue":"15","key":"413_CR103","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u201363.","journal-title":"Blood"},{"issue":"11","key":"413_CR104","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","volume":"54","author":"AJ Kansagra","year":"2019","unstructured":"Kansagra AJ, et al. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transpl. 2019;54(11):1868\u201380.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"413_CR105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813\u201322.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"413_CR106","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119\u201322.","journal-title":"Cancer J"},{"key":"413_CR107","doi-asserted-by":"crossref","unstructured":"Porter, D.L., et al., Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 2015. 7(303): p. 303ra139.","DOI":"10.1126\/scitranslmed.aac5415"},{"issue":"23","key":"413_CR108","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/blood.V126.23.1324.1324","volume":"126","author":"TJ Fry","year":"2015","unstructured":"Fry TJ, et al. Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed\/Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 2015;126(23):1324.","journal-title":"Blood"},{"issue":"1","key":"413_CR109","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"413_CR110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11864-020-0706-6","volume":"21","author":"T Badar","year":"2020","unstructured":"Badar T, Shah NN. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Curr Treat Options Oncol. 2020;21(2):16.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"413_CR111","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"26","key":"413_CR112","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323.","journal-title":"Blood"},{"key":"413_CR113","unstructured":"Davila, M.L., et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014. 6(224): p. 224ra25."},{"issue":"8","key":"413_CR114","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371.","journal-title":"Cancer Discov"},{"issue":"3","key":"413_CR115","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","volume":"42","author":"C Traube","year":"2014","unstructured":"Traube C, et al. Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU*. Crit Care Med. 2014;42(3):656\u201363.","journal-title":"Crit Care Med"},{"key":"413_CR116","first-page":"1","volume":"40","author":"JL McNeer","year":"2020","unstructured":"McNeer JL, et al. Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"413_CR117","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","volume":"123","author":"TD Buitenkamp","year":"2014","unstructured":"Buitenkamp TD, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123(1):70\u20137.","journal-title":"Blood"},{"issue":"1","key":"413_CR118","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12348","volume":"162","author":"F Meyr","year":"2013","unstructured":"Meyr F, et al. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Br J Haematol. 2013;162(1):98\u2013106.","journal-title":"Br J Haematol"},{"issue":"6","key":"413_CR119","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/pbc.24918","volume":"61","author":"JK Hitzler","year":"2014","unstructured":"Hitzler JK, et al. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2014;61(6):1126\u20138.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"413_CR120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/hematology.2019000017","volume":"2019","author":"A Winters","year":"2019","unstructured":"Winters A, Gore L. Moving immunotherapy into the front line in ALL. Hematol Am Soc Hematol Educ Program. 2019;2019(1):209\u201317.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"413_CR121","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","volume":"7","author":"E Mejstrikova","year":"2017","unstructured":"Mejstrikova E, et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7(12):659.","journal-title":"Blood Cancer J"},{"issue":"10","key":"413_CR122","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20136.","journal-title":"Nat Med"},{"issue":"10","key":"413_CR123","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"key":"413_CR124","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357\u201362.","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"413_CR125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395.","journal-title":"Cancer Discov"},{"key":"413_CR126","doi-asserted-by":"crossref","unstructured":"Bagashev, A., et al., CD19 Alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol Cell Biol, 2018. 38(21).","DOI":"10.1128\/MCB.00383-18"},{"issue":"5","key":"413_CR127","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"J Fischer","year":"2017","unstructured":"Fischer J, et al. CD19 Isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40(5):187\u201395.","journal-title":"J Immunother"},{"issue":"22","key":"413_CR128","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","volume":"3","author":"V Pillai","year":"2019","unstructured":"Pillai V, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539\u201349.","journal-title":"Blood Adv"},{"issue":"20","key":"413_CR129","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u201310.","journal-title":"Blood"},{"issue":"18","key":"413_CR130","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","volume":"130","author":"I Nagel","year":"2017","unstructured":"Nagel I, et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood. 2017;130(18):2027\u201331.","journal-title":"Blood"},{"issue":"10","key":"413_CR131","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499\u2013503.","journal-title":"Nat Med"},{"key":"413_CR132","doi-asserted-by":"crossref","unstructured":"Sasaki, K., et al., Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2019. 134(Supplement_1): p. 1296.","DOI":"10.1182\/blood-2019-128619"},{"issue":"15","key":"413_CR133","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","volume":"125","author":"EJ Jabbour","year":"2019","unstructured":"Jabbour EJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019;125(15):2579\u201386.","journal-title":"Cancer"},{"issue":"Supplement 1","key":"413_CR134","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","volume":"132","author":"R Gardner","year":"2018","unstructured":"Gardner R, et al. Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):278.","journal-title":"Blood"},{"issue":"5","key":"413_CR135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan J, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood. 2020;135(5):387\u201391.","journal-title":"Blood"},{"key":"413_CR136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin H, et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics. 2018;11:127\u201337.","journal-title":"Mol Ther Oncolytics"},{"key":"413_CR137","doi-asserted-by":"crossref","unstructured":"Schultz, L.M., et al., Phase I Trial using CD19\/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL). Blood, 2019. 134(Supplement_1): p. 744.","DOI":"10.1182\/blood-2019-129411"},{"issue":"4","key":"413_CR138","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328.","journal-title":"Cancer Cell"},{"issue":"5","key":"413_CR139","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"15","key":"413_CR140","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah NN, et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019;3(15):2317\u201322.","journal-title":"Blood Adv"},{"issue":"2","key":"413_CR141","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","volume":"130","author":"CL Nobles","year":"2020","unstructured":"Nobles CL, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest. 2020;130(2):673\u201385.","journal-title":"J Clin Invest"},{"issue":"5","key":"413_CR142","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney OC, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129(5):2123\u201332.","journal-title":"J Clin Invest"},{"issue":"5","key":"413_CR143","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/17474086.2020.1753501","volume":"13","author":"M Namuduri","year":"2020","unstructured":"Namuduri M, Brentjens RJ. Enhancing CAR T cell efficacy: the next step toward a clinical revolution? Expert Rev Hematol. 2020;13(5):533\u201343.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"413_CR144","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh N, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10(4):552\u201367.","journal-title":"Cancer Discov"},{"key":"413_CR145","doi-asserted-by":"crossref","unstructured":"Masih, K.E., et al., Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance. Blood, 2019. 134(Supplement_1): p. 2744.","DOI":"10.1182\/blood-2019-130796"},{"issue":"9","key":"413_CR146","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva O, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020;135(9):597\u2013609.","journal-title":"Blood"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00413-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-020-00413-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00413-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:08:51Z","timestamp":1696586931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-020-00413-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":146,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s40272-020-00413-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"29 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FAD serves on the peer-to-peer speaker\u2019s bureau for Servier Pharmaceuticals. WLC is funded by the NCI (R01 CA140729-05), Hyundai Hope on Wheels, Alex\u2019s Lemonade Stand, the Perlmutter Cancer Center Arline and Norman M. Feinberg Pilot Grant for Lymphoid Malignancies, and the Perlmutter Cancer Center (P30 CA016087). JP is supported by St. Baldrick\u2019s Foundation (fellowship award, 524986) and an Alex\u2019s Lemonade Stand Foundation Young Investigator Grant. SJ is supported by the Pediatric Cancer Foundation Fellowship Training Grant. EAR receives research funding from the NCI (CA98543) and Pfizer and is a KiDS of NYU Foundation Professor of Pediatrics. GCY has no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}